Document is current

Article History

Received: 26 September 2025

Accepted: 6 November 2025

First Online: 17 January 2026

Declarations

:

: H.L received research support by AMGEN and Sanofi; and was speaker or participated in advisory boards for Janssen, BMS, Pfizer, Oncopetides, Menarini/Stemline, and GSK. E.T. was in advisory boards for Amgen, AstraZeneca, EUSA Pharma, BMS, GSK, J&J, Menarini/Stemline, Pfizer, Sanofi, and Takeda; received honoraria from Amgen, Antengene, AstraZeneca, EUSA Pharma, BMS, Forus, GSK, J&J, Menarini/Stemline, Novartis, Pfizer, Sanofi, Swixx, and Takeda; received research funding from Amgen, GSK, J&J, Sanofi, and Takeda; and received travel expenses from Takeda. M.B. received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, and AbbVie; served on advisory boards for Janssen and GlaxoSmithKline; and received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, and Mundipharma. S.M., C.K., J.J., A.N., S.E., J.G. and V.A. are employees of PharmaMar S.A. C.K., J.J., A.N., J.G. and V.A. are stock ownerships in PharmaMar S.A. R.D. and X.Y. are employees and stock ownerships of Medidata, a Dassault Systèmes Company. M.V.M. received honoraria derived from lectures and participation in advisory boards from Johnson & Johnson, BMS, Amgen, GSK, AbbVie, Pfizer, Regeneron, Roche, Sanofi, Oncopeptides, and Kite.